TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05511038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Injection, 2mg (equivalent to 50 µL solution for injection)
Study: NCT05621356

Intervention type: OTHER
Intervention: A nasal fluid Basophil Activation Test (BAT)
Description: a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.

Intervention type: OTHER
Intervention: A nasal fluid Basophil Activation Test (BAT)
Description: a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
Study: NCT05601245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High voltage pulsed current
Description: The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy
Description: The treatment session duration is 40 minutes.
Study: NCT06363162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry or genetic test
Description: Perform two diagnostic methods on the same sample
Study: NCT05294029

Intervention type: OTHER
Intervention: standard of care for patients with neuromotor disability
Description: clinical examination, radiological, biological and physiological examinations.
Study: NCT06016816

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral endoscopic sphenopalatine ganglion block
Description: After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
Study: NCT06226402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 3% nebulizer
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic saline 3%
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
Study: NCT06166836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1553
Description: D1553 orally taken，600mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D1553
Description: D1553 orally taken，600mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1553
Description: D1553 orally taken，600mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1553
Description: D1553 orally taken，600mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1553
Description: D1553 orally taken，600mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018（Ifebemtinib）
Description: IN10018 orally taken once daily at approximately the same time each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018（Ifebemtinib）
Description: IN10018 orally taken once daily at approximately the same time each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018（Ifebemtinib）
Description: IN10018 orally taken once daily at approximately the same time each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018（Ifebemtinib）
Description: IN10018 orally taken once daily at approximately the same time each day
Study: NCT06450587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAT
Description: Measurement of Intraocular Pressure (IOP)
Study: NCT05002920

Intervention type: PROCEDURE
Intervention: alveolar bone grafting
Description: the surgery of alveolar bone graft for alveolar defect in cleft patients
Study: NCT05320497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent cap
Description: Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
Study: NCT05154370

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
Study: NCT06280014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
Study: NCT06391528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversalis Fascia Plane Block
Description: application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
Study: NCT04241874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Respiratory support through mechanical ventilator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Respiratory support through mechanical ventilator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Respiratory support through mechanical ventilator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Respiratory support through mechanical ventilator
Study: NCT04747275

Intervention type: DRUG
Group type: OTHER
Intervention: Liquid stable levothyroxine (L-T4) Tirosint-SOL
Description: Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Liquid stable levothyroxine (L-T4) Tirosint-SOL
Description: Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Oral tablet levothyroxine (L-T4)
Description: Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Oral tablet levothyroxine (L-T4)
Description: Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
Study: NCT05297721

Intervention type: OTHER
Intervention: Knowledge
Description: Measuring the level of knowledge about skin tears
Study: NCT05601635

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ButyraGen™
Description: ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ButyraGen™
Description: ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
Study: NCT06381440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat device (Hocoma AG, Volketswil, Switzerland).
Description: Robot Assisted Gait Training device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat device (Hocoma AG, Volketswil, Switzerland).
Description: Robot Assisted Gait Training device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking training
Description: Self-paced supervised walking training
Study: NCT04897321

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: MESNA
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide

Intervention type: DRUG
Group type: OTHER
Intervention: B7-H3 CAR T cells
Description: The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
Study: NCT05139797

Intervention type: OTHER
Intervention: EchoNet-LVH screening for cardiac amyloidosis
Description: An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.
Study: NCT06562569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive cervical vagal nerve stimulation ncVNS
Description: The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
Study: NCT06170957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified pacifier
Description: In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times.
Study: NCT05773131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR collaborative visualization system
Description: Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
Study: NCT06364163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herring oil concentrate
Description: Capsules containing herring oil concentrate, taken daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Capsules containing control oil, taken daily for 8 weeks.
Study: NCT05891821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody
Study: NCT05486234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias
Description: Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
Description: Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
Study: NCT05408000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketofol vs propofol
Description: Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketofol vs propofol
Description: Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
Study: NCT04833439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Low-caloric, low-protein, plant-based diet regiment for 3 days
Study: NCT06393283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragm Training
Description: Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
Study: NCT06072014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
Study: NCT05411302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental health supportive text messages
Description: Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
Study: NCT06124079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPY interactive messaging service
Description: 3 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The three versions differ in the motivational techniques interspersed throughout the OPY experience.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
Study: NCT05147779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT06031909

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal frailty assessment
Description: Different domains are assessed during hospital stay, these include:~* Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~* Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~* Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~* Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~* Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle.
Study: NCT04506112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation
Description: Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
Study: NCT06044324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
Study: NCT05304364

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Product: Naltrexone
Description: Naltrexone Implant
Study: NCT05765097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas treatment
Description: five to seven days treatment by artificial pancreas system
Study: NCT05856240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Stress & Emotions Group (MSEG)
Description: The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul \& Caver, 2021 for original protocol description).
Study: NCT06288035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.